Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Journal of Biotechnology and Strategic Health Research ; 5(3):178-184, 2021.
Article in Turkish | CAB Abstracts | ID: covidwho-1935003

ABSTRACT

SARS Cov-2 virus has spread rapidly all over the world, and since March 2020, it has been declared a worldwide pandemic by the World Health Organization (WHO). The general symptoms of COVID-19 are fever, fatigue, cough, myalgia, dyspnea, headache, sore throat and pneumonia. The most common oral symptom in COVID-19 is taste disorders, which is seen in 45% of patents. In addition, various oral mucosal lesions such as herpetiform and aphthous-like lesions, candidiasis and Kawasak-like lesions can be observed in patents. The purpose of this revew study is to examine the mouth findings seen in COVID-19 disease.

2.
Mediterranean Journal of Infection, Microbes and Antimicrobials ; 10, 2021.
Article in English | EMBASE | ID: covidwho-1614127

ABSTRACT

The current outbreak of the Coronavirus, severe acute respiratory syndrome Coronavirus-2, which originated in the Wuhan province of the People's Republic of China became a pandemic. Although the clinical findings of the infection vary in adults, the most common symptoms are fever, dry cough, and shortness of breath. The diagnosis of the Coronavirus disease-2019 (COVID-19) is made by clinical symptoms, laboratory tests, and radiological methods. Many drugs such as antivirals, antibiotics, and corticosteroids are used in the treatment of COVID-19. For the successful control of the pandemic, prevention strategies are the key. There is strong consensus that, in addition to wearing masks, hand hygiene, and social distancing, an effective COVID-19 vaccine is probably the most effective approach to sustainably control the pandemic. In this article, current information about the pathogenesis, epidemiology, risk groups, diagnosis, treatment, prevention strategies, and vaccination of the disease in the first year of the COVID-19 pandemic are discussed.

3.
Mediterranean Journal of Infection, Microbes and Antimicrobials ; 10(9), 2021.
Article in English | GIM | ID: covidwho-1190571

ABSTRACT

The use of saliva samples for the diagnosis of severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) provides several advantages over the use of nasopharyngeal (NP) swabs, such as comfort, ease of self-collection, less use of personal protective equipment, and protection of healthcare personnel from transmission. This review included current studies using saliva samples for the detection of SARS-CoV-2, comparing its sensitivity, cycle threshold, and specificity with those of NP swab. In the literature, the sensitivity rates of saliva samples in the diagnosis of SARS-CoV-2 ranged from 70% to 98%. Despite different opinions, we concluded that saliva is a reliable sample for the detection of SARS-CoV-2. However, studies with large samples and comparing different diagnostic methods are needed to reach precise and reliable results and include saliva collection in diagnostic guidelines.

4.
Acta Medica Mediterranea ; 37(1):667-671, 2021.
Article in English | Scopus | ID: covidwho-1134618

ABSTRACT

Introduction: The outbreak of the new coronavirus disease 2019 (COVID-19) has become the most significant global health threat in the World. We do not have well-established guidelines for cancer patients. We aimed to clarify chemotherapy's oncologic outcomes in patients with active cancer and asymptomatic COVDI 19 disease. Material and methods: This study is single-center research and designed prospectively. Only patients who were receiving intravenous systemic chemotherapy were selected and tested for COVID19 Results: During the peak period of the COVID-19 pandemic for Turkey, we started the study and analyzed 198 patients. Eighty (40%) patients were male, and 118 (60%) patients were female. Following the analysis, there was no nasal and pharyngeal swab specimen PCR positive patient, but 7 (3.5%) of 199 patients had blood antibody test positive and received their regular chemotehrapies. No patient died during the 90 days follow up. Conclusions: Even though we cannot generalize, emergent chemotherapies can administered to the COVID-19 patients if the patient did not have any symptoms for COVID-19. © 2021 A. CARBONE Editore. All rights reserved.

SELECTION OF CITATIONS
SEARCH DETAIL